中医综合方案联合化疗治疗Ⅳ期非小细胞肺癌的多中心随机对照研究《北京中医药》杂志创刊40年主编寄语
Multi⁃centered randomized controlled study of Chinese medicine integrated with chemotherapy for stage Ⅳ non⁃small cell lung cancer
- 北京中医药 2022年41卷第1期 页码：2-6
- 作者机构：
1.中国中医科学院广安门医院肿瘤科，北京 100053
2.中日友好医院中西医结合肿瘤内科，北京 100029
3.广州中医药大学第一附属医院肿瘤科，广州 510405
4.湖南省中医药研究院附属医院肿瘤科，长沙 410006
5.山西省肿瘤医院中医科，太原 030013
6.安徽医科大学第一附属医院中西医结合肿瘤科，合肥 230038
7.辽宁省肿瘤医院中西医结合科，沈阳 110042
8.新疆维吾尔自治区中医医院肿瘤科，乌鲁木齐 830000
9.浙江省中医院肿瘤科，杭州 310053
- 作者简介：
宋丽君，女，39岁，博士研究生。研究方向：恶性肿瘤的中医药防治和循证评价研究。
林洪生，E-mail：drlinhongsheng@163.com
- 基金信息：国家中医药行业科研专项(201307006);国家国际科技合作专项(2013DFA325)
DOI：10.16025/j.1674-1307.2022.01.001
中图分类号：
扫 描 看 全 文
宋丽君，马雪娇，郑佳彬，等.中医综合方案联合化疗治疗Ⅳ期非小细胞肺癌的多中心随机对照研究［J］.北京中医药，2022，41（1）：2-6.
SONG LI⁃jun,MA Xue⁃jiao,ZHENG Jia⁃bin,et al.Multi⁃centered randomized controlled study of Chinese medicine integrated with chemotherapy for stage Ⅳ non⁃small cell lung cancer[J]. Beijing Journal of Traditional Chinese Medicine,2022,41(01):2-6.
宋丽君，马雪娇，郑佳彬，等.中医综合方案联合化疗治疗Ⅳ期非小细胞肺癌的多中心随机对照研究［J］.北京中医药，2022，41（1）：2-6. DOI： 10.16025/j.1674-1307.2022.01.001.
SONG LI⁃jun,MA Xue⁃jiao,ZHENG Jia⁃bin,et al.Multi⁃centered randomized controlled study of Chinese medicine integrated with chemotherapy for stage Ⅳ non⁃small cell lung cancer[J]. Beijing Journal of Traditional Chinese Medicine,2022,41(01):2-6. DOI： 10.16025/j.1674-1307.2022.01.001.
摘要
目的,2,验证中医综合方案联合化疗治疗Ⅳ期非小细胞肺癌的疗效和安全性。,方法,2,通过多中心、前瞻性随机对照设计，纳入Ⅳ期非小细胞肺癌患者263例，随机分为观察组135例，对照组128例。观察组给予标准化疗方案联合中医综合方案，对照组接受单纯标准化疗方案。21~28 d为1个周期，连续治疗2个周期后，评估疗效和安全性。,结果,2,治疗2个周期后，观察组患者身体健康领域评分高于对照组（,P<,0.05），观察组身体健康、情绪健康和肺癌其他情况3个领域评分均显著高于治疗前（,P<,0.05）；观察组中医症状总有效率优于对照组（,P,<,0.05）；观察组食欲下降、呕吐总发生率及≥3级食欲下降发生率均低于对照组（,P,<,0.05）；实体瘤疗效2组间差异无统计学意义（,P,>,0.05）。,结论,2,Ⅳ期非小细胞肺癌患者采用中医综合方案联合化疗较单纯化疗在肿瘤控制率方面疗效相当，但能够显著改善中医症状，降低消化道不良反应的发生，提高患者生活质量。
Abstract
Objective,2,To verify the efficacy and safety of comprehensive TCM regimen combined with chemotherapy in the treatment of stage IV non-small cell lung cancer.,Methods,2,A total of 263 patients with stage Ⅳ non-small cell lung cancer were enrolled in this study in a multi-centered，prospective randomized controlled design. They were randomly divided into a observation group（,n,=135） and a control group（,n,=128）.The observation group received standard chemotherapy combined with TCM comprehensive regimen，while the control group received standard chemotherapy alone.The efficacy and safety were evaluated after 2 consecutive cycles with 21~28 days as one circle.,Results,2,After 2 cycles，the PWB（Physical Well-Being） score in test group was significantly higher than that in control group.The three Liang Yu scores of physical health， emotional health and other conditions of lung cancer in observation group were significantly higher than those before treatment （,P,<,0.05）.The total effective rate of TCM symptoms in observation group is better than that in control group（,P,<,0.05）.The total incidence of anorexia，vomiting and≥3 grade anorexia in observation group were lower than those in control group（,P,<,0.05）.There was no statistical difference in the efficacy of solid tumor between the two groups（,P,>,0.05）.,Conclusion,2,Patients with stage Ⅳ non-small cell lung cancer who adopt the comprehensive regimen of traditional Chinese medicine combined with chemotherapy have the same effect as chemotherapy alone in terms of tumor control rate，but can significantly improve the symptoms of TCM，reduce the occurrence of adverse reactions in gastrointestinal tract，and make the patients have a better quality of life.
关键词
非小细胞肺癌Ⅳ期中医综合治疗化疗不良反应中医症状生活质量
Keywords
Non-small cell lung cancer（NSCLC）stage Ⅳcomprehensive treatment of traditional Chinese medicinechemotherapyadverse reactionTCM symptomquality of life
references
SUNG H,FERLAY J,SIEGEL RL,et al.Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2021,71(3):209-249.
郑荣寿,孙可欣,张思维,等.2015年中国恶性肿瘤流行情况分析[J].中华肿瘤杂志,2019,41(1):19-28.
MOVSAS B.Innovative treatment strategies in locally advanced and/or unresectable non-small cell lung cancer[J].Cancer Control,2000,7(1):25-34.
PAZ-ARES L,LUFT A,VICENTE D,et al.Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer[J].N Engl J Med,2018,379(21):2040-2051.
支修益,吴一龙,马胜林,等.原发性肺癌诊疗规范(2011年版)[J].中国肺癌杂志,2012,15(12):677-688.
DETTERBECK FC,BOFFA DJ,TANOUE LT.The new lung cancer staging system[J].Chest,2009,136(1):260-271.
林洪生.恶性肿瘤中医诊疗指南[M].北京:人民卫生出版社,2014.
OKEN MM,CREECH RH,TORMEY DC,et al.Toxicity and response criteria of the eastern cooperative oncology group[J].Am J Clin Oncol,1982,5(6):649-655.
ETTINGEＲ DS,WOOD DE,AISNEＲ DL,et al.Non-small cell lung cancer,Version 5.2017,NCCN clinical practice guidelines in oncology［J］.J Nat Compr Can Net,2017,15(4):504-535．
WAN C,ZHANG C,CAI L,et al.Psychometric properties of the Chinese version of the FACT-L for measuring quality of life in patients with lung cancer[J].Lung Caner,2007,56(3):415-421.
郑筱萸.中药新药临床研究指导原则( 试行) [M].北京:中国医药科技出版社,2002:216．
TROTTI A,COLEVAS AD,SETSER A,et al.CTCAE v3.0:development of a comprehensive grading system for the adverse effects of cancer treatment[J].Semin Radiat Oncol,2003,13(3):176-181.
CHOI HC,KIM JH,KIM HS,et al.Comparison of the RECIST 1.0 and RECIST 1.1 in non-small cell lung cancer treated with cytotoxic chemotherapy[J].J Cancer,2015,6(7):652-657.
孙燕,林洪生,朱允中,等.长春瑞滨合并顺铂(NP)加参一胶囊或安慰剂治疗晚期非小细胞肺癌的多中心双盲随机临床研究报告[J].中国肺癌杂志,2006,9(3):254-258.
林丽珠,周岱翰,郑心婷.中医药提高晚期非小细胞肺癌患者生存质量的临床观察[J].中国中西医结合杂志,2006,26(5):389-393.
KWON CY,LEE B,KONG M,et al.Effectiveness and safety of herbal medicine for cancer-related fatigue in lung cancer survivors:a systematic review and meta-analysis[J].Phytother Res,2021,35(2):751-770.
GRASSI L,BERARDI MA,RUFFILLI F,et al.Role of psychosocial variables on chemotherapy-induced nausea and vomiting and health-related quality of life among cancer patients:a European study[J].Psychother Psychosom,2015,84(6):339-347.
SCHWARTZBERG L,HARROW B,LAL LS,et al.Resource utilization for chemotherapy-induced nausea and vomiting events in patients with solid tumors treated with antiemetic regimens[J].Am Health Drug Benefits,2015,8(5):273-282.
0
浏览量
0
下载量
0
CSCD
- Meta-XML下载
- BibTeX下载
- Endnote下载
- RefMan 下载
- NoteExpress下载
- NoteFirst下载
关联资源
相关文章
相关作者
相关机构
- 技术支持由北京北大方正电子有限公司提供 京ICP备18046208号-2
京公网安备 11010102006710号 - 本系统建议在Chrome、 IE9+ 以上版本浏览器阅读本站内容，360浏览器请切换至极速模式
- Cookies帮助我们提供服务并提供个性化体验。使用本网站，即表示您同意我们使用Cookies